Results 1 to 1 of 1
03-27-2011, 04:50 PM #1
APP Pharmaceuticals Issues A Nationwide Voluntary Recall Of Irinotecan Hydrochloride
APP Pharmaceuticals, Inc., (APP) announced today that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer. This recall is being conducted as a precautionary measure and there have been no reports to dates of adverse events related to the recalled products.